Brussels-based biopharma UCB will acquire Candid Therapeutics for up to $2.2 billion, comprised of a $2.0 billion upfront cash payment and $200 million in milestones. The deal centers on Candid's lead asset, Cizutamig, a T-cell engager (TCE) designed to treat autoimmune diseases by inducing an 'immune reset.' This acquisition is a strategic pivot for UCB to diversify beyond its blockbuster drug Bimzelx and secure a leadership position in next-generation B-cell depletion therapies. The transaction underscores a key 2026 M&A trend where large pharma is paying significant premiums for clinical-stage platforms that offer 'pipeline-in-a-product' potential, prioritizing capital efficiency and high revenue visibility.
- Acquirer
- UCB
- Target
- Candid Therapeutics
- Transaction Value
- Up to $2.2 Billion
- Upfront Consideration
- $2.0 Billion (Cash)
- Contingent Milestones
- $200 Million
- Lead Asset
- Cizutamig (BCMAxCD3 Bispecific T-cell engager)
- Strategic Driver
- Dominate the 'immune reset' category and diversify beyond the IL-17 franchise.
- Expected Close
- Late Q2 or early Q3 2026
- Acquirer's Financial Advisor
- Lazard
- Target's Financial Advisors
- Jefferies, Goldman Sachs, BofA Securities
- Acquirer's Legal Counsel
- Covington & Burling
- Target's Legal Counsel
- Cooley LLP
Brussels-based biopharma giant UCB announced today a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion. The deal signals a decisive move to dominate the “immune reset” category, a burgeoning frontier where oncology-born T-cell engager (TCE) technology is repurposed to treat refractory autoimmune diseases.
Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:
đź’Ľ When Claude Code Marries Due Diligence!
The transaction involves a $2.0 billion upfront cash payment, supplemented by $200 million in potential milestone payments. For UCB, the acquisition is a strategic pivot designed to diversify its portfolio beyond the blockbuster success of IL-17A/F inhibitor Bimzelx and secure a leadership position in next-generation B-cell depletion therapies.
The Strategic Rationale: Beyond the IL-17 Dominance
UCB enters this transaction from a position of commercial strength. In fiscal year 2025, UCB reported revenues of €7.7 billion, driven by a 200% surge in Bimzelx sales. However, with patent cliffs looming for legacy assets and intensifying competition from AbbVie and Novartis, CEO Jean-Christophe Tellier is aggressively pursuing an inorganic growth strategy focused on high-science, high-unmet-need indications.
Candid Therapeutics, which recently transitioned to the public markets through a reverse merger with Rallybio in March 2026, possesses one of the industry’s most advanced TCE pipelines for immunology. The acquisition allows UCB to bypass years of early-stage platform development by absorbing assets with established clinical proof-of-concept in oncology that are now being “transposed” into autoimmune settings.
Table 1: Transaction Summary and Deal Terms
| Metric | Details |
|---|---|
| Upfront Consideration | US $2.0 Billion (Cash) |
| Contingent Milestones | US $200 Million |
| Lead Asset | Cizutamig (BCMAxCD3 Bispecific) |
| Financial Advisors (UCB) | Lazard |
| Financial Advisors (Candid) | Jefferies, Goldman Sachs, BofA Securities |
| Legal Counsel | Covington & Burling (UCB); Cooley LLP (Candid) |
Cizutamig: The ‘Best-in-Class’ Contender
The centerpiece of the deal is Cizutamig, a bispecific T-cell engager targeting BCMA and CD3. Unlike traditional monoclonal antibodies such as Rituxan, which offer limited B-cell depletion in deep tissues, TCEs are designed to engage the patient’s own T-cells to aggressively eliminate pathogenic B-cells and plasma cells. This “immune reset” has shown the potential to induce long-term remission in diseases like Systemic Lupus Erythematosus (SLE) and Myasthenia Gravis.
UCB’s existing immunology pipeline, bolstered by the 2025 acquisition of rights from Antengene, now covers a broad spectrum of B-cell targets. By integrating Candid’s portfolio, UCB achieves “platform-level” optionality across multiple modalities:
- Cizutamig (BCMAxCD3): Currently in Phase 2 readiness for 10+ autoimmune indications.
- CND261 (CD20xCD3): Targeted at B-cell populations across rheumatoid arthritis and systemic sclerosis.
- CND319/460: Preclinical trispecific assets designed for deeper, multi-antigen targeting.
Industry Implications: 2026 as the Year of Immunology M&A
The UCB-Candid deal reflects a broader biotech M&A trend in 2026 where strategic buyers are prioritizing clinical-stage assets with high “revenue visibility.” According to recent analysis by Goldman Sachs and McKinsey, the life sciences sector is experiencing a “normalization phase” following a volatile 2025. Large-cap pharma companies are sitting on approximately $2.1 trillion in dealmaking firepower, and the competitive landscape for T-cell engagers for autoimmune diseases has reached a fever pitch.
For investment professionals, this acquisition underscores a shift in valuation premiums. Buyers are increasingly willing to pay significant upfront multiples for platforms that offer “pipeline-in-a-product” potential. Candid’s ability to target ten indications with a single lead asset makes it a highly capital-efficient acquisition for UCB, even at a $2.2 billion valuation.
The Advisory Bench
The transaction’s complexity—involving a newly public target and cross-border regulatory considerations—required a heavy-hitting advisory lineup. Lazard served as the sole financial advisor to UCB, maintaining its long-standing relationship with the Belgian firm. Candid relied on a powerhouse joint-lead team of Jefferies and Goldman Sachs, reflecting the target’s rapid ascent from a $370 million private series-D in 2024 to a multi-billion dollar exit in 2026.
The deal is expected to close in late Q2 or early Q3 2026, pending customary antitrust clearances. As UCB integrates these assets, the focus shifts to whether cizutamig can maintain its safety profile in large-scale Phase 2 trials, particularly regarding cytokine release syndrome (CRS)—the primary hurdle for T-cell engagers transitioning from the oncology ward to the outpatient immunology clinic.
